Application of CD271+ human bone marrow-derived: Stem cells for ischaemic heart disease therapy

Ali Ghodsizad, Mina Farag, Matthias Loebe, Eric Lumsden, Christoph Phiechaczek, Matthias Karck, Arjang Ruhparwar

Research output: Contribution to journalArticle


Cell transplantation for myocardial regeneration has been shown to have beneficial effects on cardiac function after myocardial infarction. Here, we discuss the application of CD 271+ bone marrow-derived stem cells (BMCs) as novel markers for the enrichment of mesenchymal somatic stem cells. Injection of BMCs into ischaemic myocardium during surgery has been shown to be both feasible and safe. This novel approach might hold promise as an alternative to medical management in patients with severe ischaemic heart failure who are ineligible for conventional revascularisation.

Original languageEnglish (US)
Pages (from-to)280-282
Number of pages3
JournalEuropean Cardiology
Issue number4
StatePublished - Jun 2011



  • Bone marrow-derived stem cells
  • Ischaemic heart disease
  • Somatic stem cells
  • Stem cell therapy

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this